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Progressive narrowing of the central airways due to diffuse inﬂammation is a potential life-threatening
condition. A number of diseases have been described as possible causes. We present two siblings with
severe central airway obstruction. Despite considerable efforts we have not been able to match the
clinical appearance of our patients with the diagnostic criteria of any of the disease entities known to
cause this condition.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Case reports
Patient no 1 is a man who was 49 years old at the time of
admission. He is a never-smoker who has worked several years as a
carpenter. He had been occupationally exposed to stone dust, but
not to asbestos. Patient no 2 is his two years younger sister whowas
admitted to our hospital, also at the age of 49. She is a never-
smoking woman, working in an ofﬁce, and had no known expo-
sure to harmful dusts. They were both previously healthy, the
brother born deaf, though, assumingly because his mother was
infected with rubella during pregnancy. They have no known he-
reditary diseases, and there are no other siblings. None of them
have had any trauma or had a tracheostoma, nor have they had
previous recurrent infections.
Both presented with worsening dyspnoe, cough and non-
characteristic chest pain over a period of 4e6 months, and both
had been treated by their GPs with antibiotics, without any
improvement.
At the time of admission, patient no 1 had spirometry values
consistent with airway obstruction with FVC 4.5 l (98% of pre-
dicted), FEV1 2.7 l (73%). The sister’s initial spirometry showed FVC, anti-neutrophil cytoplasmic
V, cytomegalovirus; CRP, C-
fusing capacity of the lung for
one second; FVC, forced vital
factor; RPC, relapsing poly-
l lung capacity.
æverud), uxfrbo@ous-hf.no
xplﬁ@ous-hf.no (P. Finstad),
-NC-ND license.2.6 l (77%), FEV1 1.2 l (41%), FEV1/FVC 0.46, and a considerable
compromised inspiratory curve. They both had TLC between 70 and
80% predicted, RV 80e90% and DLCO within the normal range on
serial measurements. Both had an elevated CRP, 61 for patient no 1
and 47 for patient no 2. Blood leukocyte and eosinophils were
normal, there was no hypercalcemia, and ACE levels were in the
lower normal area.
Extensive diagnostic investigations were undertaken for both
patients. CT-scans showed diffuse circumferential thickening of the
trachea and main bronchi, including pars membranacea tracheae,
scattered intramural calciﬁcation and considerable narrowing of
the tracheal and bronchial lumina (Figs. 1 and 2). There were no
external compression or emphysema.
Bronchoscopy revealed a generally swollen and inﬂamed mu-
cosawith visually poorly deﬁned tracheal and bronchial cartilage in
both patients. There was a ﬁxed airway narrowing affecting the
trachea and main bronchi, with no apparent dynamic changes
throughout the respiratory cycle. After a period of medical treat-
ment, repeated bronchoscopy showed reduced inﬂammatory
changes but was otherwise similar.
There was no growth of mycobacteria, other bacteria or vira in
lavage ﬂuid from the airways. Bronchial biopsies revealed chronic
unspeciﬁc inﬂammation. There were no signs of granulomatous
inﬂammation, vasculitis or amyloidosis in a Congo red staining.
Unfortunately there was no cartilage in the bronchial biopsies.
Additional biopsies from auricular cartilage, conchae and cost-
osternal cartilage were normal. All biopsies obtained from the
siblings were compared, and deemed identical. Electron micro-
scopic evaluation of the biopsies has not been performed.
We have not performed biopsies of subcutaneous fat or rectal
mucosa.
Fig. 1. CT-scan of patient no 1 just below carina with thickening of the airway walls
and compression of the lumina of both main bronchi.
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both cyclophosphamide and prednisolon, did not show any activity
in trachea, bronchi or lung parenchyma.
CT of the sinuses were normal apart from minor edema in the
right maxillar sinus of patient no 2.
Serologic testing was negative for CMV and Mycoplasma pneu-
moniae, Bordetella pertussis, ANA, ANCA and RF. Skin testing for
aspergillus was negative, and the total IgE was normal. Renal func-
tion was normal, and there was no proteinuria or signs of nephritis.
Serum-electrophoresis showed non-speciﬁc inﬂammation.
Both patients have received immunosuppressive therapy with
prednisolone, and cyclophosphamide was added. Patient no 1
received azithromycin as immunomodulation, and patient no 2 has
received azathioprine, without any effect on symptoms. They alsoFig. 2. CT- scan from patient no 1 showing circumferential tracheal thickening (arrow)
and narrowing of the lumen.received inhalations with budesonide/formoterol, salbutamol and
ipratriopium bromide ad libitum, with uncertain effect.
Initially the condition deteriorated for both patients with pro-
gressive worsening of symptoms, inspiratory stridor and declining
spirometric values. The condition of patient no 1 has been stable
during the last two years with FVC 2.8 l (63%) and FEV1 0.9 l (26%).
Cyclophosphamide has been replaced by azathioprine, and he still
receives prednisolone and azathioprine, 5 years after the initial
presentation.
The rapid deterioration of patient no 2 was initially halted when
treatment was instituted. After a time she progressed, though, and
eventually received rituximab, without any signiﬁcant effect. There
is, however, still a minor effect of large doses of steroids. She still
suffers from considerable obstruction of the central airways,
resembling what is seen in patient no 1, her latest spirometry
values being FVC 2.7 l (83%), FEV10.8 l (29%) (Fig. 3). In the course of
the disease the obstruction of her left main bronchus was subtotal,
requiring implantation of an endobronchial silicon stent. This was
removed after only 3 weeks due to persisting symptoms. Both
siblings have experienced several exacerbations requiring antibi-
otics and elevated steroid doses.
Due to the initial progressive nature of the condition and the
severely compromised lung function lung transplantation was
considered for both patients shortly after presentation. After con-
sultationswith the transplant center thiswas considered not to be an
option, due to the involvement of the main bronchi and the trachea.
2. Discussion
We present two siblings with severe rapidly progressive
obstruction of the central airways at the age of 49. Despite exten-
sive investigation we have not been able to reveal a diagnosis
consistent with the criteria of disease entities known to involve the
large airways, with amyloidosis, Wegener’s granulomatosis (WG)
and relapsing polychondritis (RPC) being the most likely culprits.
A diagnosis of amyloidosis is dependent on the presence of
amyloid ﬁbrils in a Congo red staining. This could not be shown in
our patients.
Neither did we ﬁnd histologic or other signs of vasculitis
as described by The American college of rheumatology and the
Chapel Hill consensus conference.1,2 Using European Medicines
Agency’s algorithm for classiﬁcation of vasculitides3 the siblings are
unclassiﬁable.
According to McAdam RPC implies combinations of chondritis
in multiple sites, such as auricles, nose or respiratory tract, a non-
erosive seronegative inﬂammatory polyarthritis, ocular inﬂamma-
tion and audiovestibular damage.4,5 In addition a histological
conﬁrmation is considered necessary if the case is not clinically
obvious.
Although not ﬁrmly established there has been some indications
of an association between the HLA genotypes DR4 and DR6 and
RPC.6 Both our patients were tested, but none of them had the
genotypes in question.
None of the siblings thus fulﬁl the criteria for RPC or WG. Do-
mestic and international consultation has not resulted in signiﬁcant
progress regarding the diagnosis.
The fact that two siblings presentwith identical complaints at the
same agemight suggest an inherited predisposition, butwehave not
been able to establish neither a plausible syndrome, nor have we
foundsimilar cases of anydiseaseentityaffecting siblings reported in
the literature. We have considered an autoimmune pathogenesis to
be likely, and that is the rationale for giving immunosuppressive
medication. In our opinion the condition resembles RP more than
WG or amyloidosis, but as they have only single organ involvement
we have been unable to formally classify it as such.
Fig. 3. Spirometry of patient no 2, 4 years after presentation, showing both inspiratory and expiratory obstruction.
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that might help us unveil a diagnosis.Conﬂict of interest
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